2-(butanoylamino)thiophene-3-carboxamide | 896680-70-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 2-(butanoylamino)thiophene-3-carboxamide
• CAS: 896680-70-9
• 化学式: C₉H₁₂N₂O₂S
• mdl: MFCD04430452
• 分子量: 212.272
• InChiKey: QFUOJZBSCYPNSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  100
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(butanoylamino)thiophene-3-carboxamide 在 盐酸 、 5%-palladium/activated carbon 、 氢气 、 溴 、 sodium acetate 、 potassium carbonate 、 溶剂黄146 、 三乙胺 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 、 正己烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 44.5h， 生成 (-)-N-(3-aminopropyl)-N-[1-(3-benzyl-4-oxothieno[2,3-d]pyrimidin-2-yl)propyl]-4-methylbenzamide hydrochloride
  参考文献：
  名称：

  Discovery of (+)-N-(3-Aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a Kinesin Spindle Protein Inhibitor and Potential Anticancer Agent

  摘要：

  Structure activity relationship analysis identified (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), from a series of novel kinesin spindle protein (KSP) inhibitors, as exhibiting both excellent biochemical potency and pharmaceutical properties suitable for clinical development. The selected compound arrested cells in mitosis leading to the formation of the monopolar spindle phenotype characteristic of KSP inhibition and induction of cellular death. A favorable pharmacokinetic profile and notable in vivo efficacy supported the selection of this compound as a clinical candidate for the treatment of cancer.

  DOI：

  10.1021/jm200629m
• 作为产物：
  描述：

  2-胺噻吩-3-羰基胺 、 丁酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以96%的产率得到2-(butanoylamino)thiophene-3-carboxamide
  参考文献：
  名称：

  Discovery of (+)-N-(3-Aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a Kinesin Spindle Protein Inhibitor and Potential Anticancer Agent

  摘要：

  Structure activity relationship analysis identified (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), from a series of novel kinesin spindle protein (KSP) inhibitors, as exhibiting both excellent biochemical potency and pharmaceutical properties suitable for clinical development. The selected compound arrested cells in mitosis leading to the formation of the monopolar spindle phenotype characteristic of KSP inhibition and induction of cellular death. A favorable pharmacokinetic profile and notable in vivo efficacy supported the selection of this compound as a clinical candidate for the treatment of cancer.

  DOI：

  10.1021/jm200629m

文献信息

• Discovery of (+)-<i>N</i>-(3-Aminopropyl)-<i>N</i>-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-<i>d</i>]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a Kinesin Spindle Protein Inhibitor and Potential Anticancer Agent
  作者：Maria-Elena Theoclitou、Brian Aquila、Michael H. Block、Patrick J. Brassil、Lillian Castriotta、Erin Code、Michael P. Collins、Audrey M. Davies、Tracy Deegan、Jayachandran Ezhuthachan、Sandra Filla、Ellen Freed、Haiqing Hu、Dennis Huszar、Muthusamy Jayaraman、Deborah Lawson、Paula M Lewis、Murali V. P. Nadella、Vibha Oza、Maniyan Padmanilayam、Timothy Pontz、Lucienne Ronco、Daniel Russell、David Whitston、Xiaolan Zheng

  DOI：10.1021/jm200629m

  日期：2011.10.13

  Structure activity relationship analysis identified (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), from a series of novel kinesin spindle protein (KSP) inhibitors, as exhibiting both excellent biochemical potency and pharmaceutical properties suitable for clinical development. The selected compound arrested cells in mitosis leading to the formation of the monopolar spindle phenotype characteristic of KSP inhibition and induction of cellular death. A favorable pharmacokinetic profile and notable in vivo efficacy supported the selection of this compound as a clinical candidate for the treatment of cancer.